[CAS NO. 116-26-7] Safranal
PRODUCTS SPECIFICATIONS [116-26-7]
DESCRIPTION [116-26-7]
Overview
| MDL | MFCD00209531 |
|---|---|
| Molecular Weight | 150.22 |
| Molecular Formula | C10H14O |
| SMILES | O=CC1=C(C)C=CCC1(C)C |
Summary
Safranal is an orally active main component of Saffron ( Crocus sativus ) and is responsible for the unique aroma of this spice. Safranal has neuroprotective and anti-inflammatory effects and has the potential for Parkinson’s disease research [1] .
In Vitro
Safranal (10-50 μM; for 1 h) dose-dependently decreases LPS-induced iNOS and COX-2 levels in both RAW264.7 cells and BMDMs
[1]
.
Safranal (10-50 μM; for 1 h) inhibits cytokine IL-6 and TNF-α production and mRNA expression in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells
[1]
.
Safranal (10, 50 μM; for 1 h followed by stimulation with 1 μg/ml of LPS for 30 min) inhibits the nuclear translocation of NF-κB and AP-1 in lipopolysaccharide (LPS)-stimulated RAW264.7 cells
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | RAW264.7 cells and bone marrow-derived macrophages (BMDMs) |
| Concentration: | 10, 50 μM |
| Incubation Time: | For 1 h prior to lipopolysaccharide (LPS) stimulation (1 µg/ml) |
| Result: |
Dose-dependently decreased LPS-induced iNOS and COX-2 levels in both RAW264.7 cells and BMDMs.
Inhibited the phosphorylation of MAPK pathway proteins extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38. Inhibited NF-κB pathway proteins IKKα/β and IκBα and the degradation of IκBα. |
RT-PCR [1]
| Cell Line: | RAW 264.7 cells |
| Concentration: | 10, 50 μM |
| Incubation Time: | For 1 h followed by stimulation with LPS (1 μg/ml) for 24 h |
| Result: | Inhibited cytokine IL-6 and TNF-α production and mRNA expression in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells. |
In Vivo
Safranal (200-500 mg/kg; PO; for 7 days) causes a slight restoration of colon length and percentage of weight loss, and the DAI score is significantly low [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Female BALB/c mice (18-20 g) (DSS-induced colitis mice) [1] |
| Dosage: | 200, 500 mg/kg |
| Administration: | PO; for 7 days |
| Result: | Caused a slight restoration of colon length and percentage of weight loss, and the DAI score is significantly low. |
Appearance
Liquid
Source
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
-20°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
DMSO : 100 mg/mL ( 665.69 mM ; Need ultrasonic)
Ethanol : 100 mg/mL ( 665.69 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.6569 mL | 33.2845 mL | 66.5690 mL |
| 5 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL |
| 10 mM | 0.6657 mL | 3.3285 mL | 6.6569 mL |
-
1.
-
2.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (16.64 mM); Suspended solution; Need ultrasonic
-
3.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (16.64 mM); Clear solution
-
4.
-
5.
Add each solvent one by one: 10% EtOH >> 90% (20% SBE-β-CD in saline)
Solubility: 2.5 mg/mL (16.64 mM); Suspended solution; Need ultrasonic
-
6.
Add each solvent one by one: 10% EtOH >> 90% corn oil
Solubility: ≥ 2.5 mg/mL (16.64 mM); Clear solution
Synonyms